糖皮质激素治疗社区获得性肺炎：系统评价与Meta分析更新
该系统评价纳入20项随机对照试验共5866例成人社区获得性肺炎患者，评估全身糖皮质激素的疗效与安全性。结果显示激素未显著降低总死亡率，但重症患者死亡率显著降低，住院和ICU时间缩短，且未增加机械通气、继发感染或消化道出血风险。轻症患者无死亡率获益，不支持常规使用。
要点
- 重症社区获得性肺炎患者使用糖皮质激素可显著降低死亡率（RR 0.73）。
- 激素治疗缩短住院时间（MD -2.13天）和ICU停留时间（MD -1.70天）。
- 轻症患者无死亡率获益，不推荐常规使用糖皮质激素。
核心结论
- 糖皮质激素可改善重症社区获得性肺炎患者的预后，降低死亡率并缩短住院时间，且不增加不良事件。
- 不支持在轻症社区获得性肺炎患者中常规使用糖皮质激素。
研究设计与样本
- 系统评价与Meta分析，纳入20项随机对照试验，共5866例成人社区获得性肺炎患者。
- 比较全身糖皮质激素与安慰剂或常规治疗，采用随机效应模型计算风险比和均数差。
主要发现
- 总死亡率无显著降低（RR 0.84；95% CI: 0.68-1.03；p = 0.10）。
- 重症社区获得性肺炎患者死亡率显著降低（n = 3326；RR 0.73；95% CI: 0.57-0.93；p = 0.01）。
- 轻症社区获得性肺炎患者无死亡率获益（n = 2451；RR 1.14；95% CI: 0.89-1.45；p = 0.31）。
- 住院时间显著缩短（n = 4175；MD -2.13天；95% CI: -3.07至-1.19；p < 0.00001），轻症缩短1.03天，重症缩短3.04天。
- ICU停留时间缩短（MD -1.70天；p = 0.005），未显著增加机械通气需求（RR 0.57；p = 0.10）、继发感染（RR 0.99；p = 0.92）或消化道出血（RR 0.80；p = 0.29）。
临床怎么用
- 对重症社区获得性肺炎患者可考虑使用全身糖皮质激素以降低死亡率和缩短住院时间。
- 轻症社区获得性肺炎患者不推荐常规使用糖皮质激素。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
Heart Lung. 2026 Sep-Oct;79:102839. doi: 10.1016/j.hrtlng.2026.102839. Epub 2026 May 17. ABSTRACT BACKGROUND: Community-acquired pneumonia (CAP) is a significant global health burden, particularly in severe cases. Corticosteroids have been proposed as adjunctive therapy to improve outcomes, though evidence remains mixed. OBJECTIVE: To determine the effect of corticosteroid therapy on mortality and morbidities in patients with CAP. METHODS: We conducted a systematic review and meta-analysis of 20 randomized controlled trials (RCTs) involving 5,866 adult patients with CAP. Studies comparing systemic corticosteroids to placebo or usual care were included. Risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel and inverse variance methods under a random-effects model. Statistical heterogeneity was assessed using the I² statistic. RESULTS: Corticosteroids did not significantly reduce overall mortality (RR 0.84; 95% CI: 0.68-1.03; p = 0.10), but a significant reduction was observed in patients with severe CAP (n = 3,326; RR 0.73; 95% CI: 0.57-0.93; p = 0.01). No mortality benefit was seen in less severe CAP (n = 2,451; RR 1.14; 95% CI: 0.89-1.45; p = 0.31). Hospital length of stay was significantly reduced with corticosteroids (n = 4,175; MD -2.13 days; 95% CI: -3.07 to -1.19; p < 0.00001), with reductions observed in both less severe (-1.03 days) and severe CAP (-3.04 days). ICU stay was also shorter in the corticosteroid group (MD -1.70 days; p = 0.005). Corticosteroids did not significantly increase the need for mechanical ventilation (RR 0.57; p = 0.10), or increase the risk of secondary infections (RR 0.99; p = 0.92), or gastrointestinal bleeding (RR 0.80; p = 0.29). CONCLUSION: Corticosteroids improve outcomes in severe CAP by reducing mortality and duration of hospitalization without increasing adverse events. Routine use in less severe CAP is not supported. PMID: 42143791 | DOI: 10.1016/j.hrtlng.2026.102839
引用
- PubMed 高证据 · 肺炎：Steroid Therapy in Community-Acquired Pneumonia: An Updated Systematic Review and Meta-Analysis
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。